The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply ...

Over the past year, the question has been coming in from everywhere – from my patients and family members, from colleagues ...

Global diabetes rates have surged, particularly in low-resource areas, revealing critical gaps in treatment access and ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Stress may be the reason people with obesity are more likely to get other metabolic diseases, such as type 2 diabetes, ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

For decades, researchers from all obesity-related disciplines have been observing the escalating prevalence of people living ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

"We have seen an alarming rise in diabetes over the past three decades, which reflects the increase in obesity, compounded by the impacts of the marketing of unhealthy food, a lack of physical ...

Diabetes is a lifestyle disease that has no cure. On this World Diabetes Day, India's top diabetologist, Dr Rajiv Kovil, ...